Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Net Income (2016 - 2024)

Arcadia Biosciences (RKDA) has disclosed Net Income for 12 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income fell 168.37% year-over-year to -$1.2 million, compared with a TTM value of -$1.7 million through Sep 2025, down 178.22%, and an annual FY2024 reading of -$2.7 million, down 231.43% over the prior year.
  • Net Income was -$1.2 million for Q3 2025 at Arcadia Biosciences, down from -$501000.0 in the prior quarter.
  • Across five years, Net Income topped out at $4.8 million in Q4 2023 and bottomed at -$16.1 million in Q4 2021.
  • Average Net Income over 5 years is -$2.8 million, with a median of -$1.3 million recorded in 2024.
  • The sharpest move saw Net Income soared 568.02% in 2023, then crashed 715.47% in 2024.
  • Year by year, Net Income stood at -$16.1 million in 2021, then surged by 93.56% to -$1.0 million in 2022, then skyrocketed by 568.02% to $4.8 million in 2023, then crashed by 100.54% to -$26000.0 in 2024, then tumbled by 4338.46% to -$1.2 million in 2025.
  • Business Quant data shows Net Income for RKDA at -$1.2 million in Q3 2025, -$501000.0 in Q2 2025, and -$26000.0 in Q4 2024.